FY2025 EPS Estimates for CRSP Cut by Cantor Fitzgerald

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Cantor Fitzgerald cut their FY2025 earnings per share estimates for CRISPR Therapeutics in a research note issued on Wednesday, February 19th. Cantor Fitzgerald analyst E. Schmidt now expects that the company will earn ($6.91) per share for the year, down from their prior estimate of ($5.08). Cantor Fitzgerald has a “Neutral” rating on the stock. The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.16) per share.

CRISPR Therapeutics (NASDAQ:CRSP) last issued its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%.

Several other equities research analysts have also recently commented on CRSP. The Goldman Sachs Group dropped their price objective on CRISPR Therapeutics from $66.00 to $57.00 and set a “neutral” rating on the stock in a research report on Thursday, February 13th. Barclays raised their target price on CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an “equal weight” rating in a research report on Wednesday, February 12th. Citigroup dropped their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating on the stock in a research report on Tuesday, February 18th. Stifel Nicolaus dropped their target price on CRISPR Therapeutics from $53.00 to $49.00 and set a “hold” rating on the stock in a research report on Thursday, February 13th. Finally, Morgan Stanley raised their target price on CRISPR Therapeutics from $30.00 to $32.00 and gave the stock an “underweight” rating in a research report on Friday, February 14th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $74.40.

CRISPR Therapeutics Price Performance

CRISPR Therapeutics stock opened at $47.91 on Friday. CRISPR Therapeutics has a one year low of $36.52 and a one year high of $91.10. The stock has a market capitalization of $4.11 billion, a PE ratio of -10.96 and a beta of 1.67. The business’s fifty day moving average is $42.25 and its 200 day moving average is $46.04.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Boston Family Office LLC increased its holdings in shares of CRISPR Therapeutics by 2.2% in the third quarter. Boston Family Office LLC now owns 9,763 shares of the company’s stock valued at $459,000 after purchasing an additional 213 shares during the period. Bedell Frazier Investment Counselling LLC increased its holdings in shares of CRISPR Therapeutics by 0.8% in the third quarter. Bedell Frazier Investment Counselling LLC now owns 26,357 shares of the company’s stock valued at $1,238,000 after purchasing an additional 218 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of CRISPR Therapeutics by 1.9% in the third quarter. The Manufacturers Life Insurance Company now owns 12,477 shares of the company’s stock valued at $586,000 after purchasing an additional 231 shares during the period. Intellectus Partners LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% in the fourth quarter. Intellectus Partners LLC now owns 7,131 shares of the company’s stock valued at $281,000 after purchasing an additional 250 shares during the period. Finally, Farrow Financial Inc. increased its holdings in shares of CRISPR Therapeutics by 1.4% in the fourth quarter. Farrow Financial Inc. now owns 20,097 shares of the company’s stock valued at $777,000 after purchasing an additional 270 shares during the period. 69.20% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at CRISPR Therapeutics

In related news, CEO Samarth Kulkarni sold 18,360 shares of the company’s stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total transaction of $1,013,472.00. Following the transaction, the chief executive officer now directly owns 171,613 shares of the company’s stock, valued at $9,473,037.60. This represents a 9.66 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 4.10% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.